M&As this week: Genesis Biotechnology Group, Betta Pharmaceuticals
Genesis Biotechnology Group has completed the acquisition of PharmOptima, which will enable the former to provide its customers a single point-of-contact for the development and co-ordination of their unique pre-clinical drug development programme.
Genesis Biotechnology Group has completed the acquisition of PharmOptima, which will enable the former to provide its customers a single point-of-contact for the development and co-ordination of their unique pre-clinical drug development programme.
"Betta Pharmaceuticals has announced its intention to acquire 77.4% stake in AnewPharma."
The acquirer company is a US-based biotechnology firm, whereas the target company is a contract research organisation also based in the US.
Betta Pharmaceuticals has announced its intention to acquire 77.4% stake in AnewPharma.
Both companies involved in the transaction are pharmaceutical organisations based in China.
The purchase consideration for the acquisition is expected to be ¥371.6m ($54.08m).